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Abstract.
The [Ph3PAu(6-MP)] complex, where 6-MPH is 6-mercaptopurine, is active against the cisplatin-
resistant cell line, mouse leukaemia L1210/DDP, as is the precursor compound [Ph3PAuCI],
suggesting that the thiolate is not critical for activity. Against the human cell lines, FaDu (squamous
cell carcinoma) and SKOV-3 (ovarian carcinoma), both [Ph3PAu(6-MP)] and [Ph3PAu(6-TG)],
where 6-TGH .is 6-thioguanine, were active. [Ph3PAu(6-MP)] was active against a murine PC6
plasmacytoma, but not as active as cisplatin.
Introduction.
The use of gold compounds in the treatment of rheumatoid arthritis is well documented [1 3].
Given the clinical success of such compounds, it is not surprising that gold derivatives have also
been examined for their potential anti-tumour activity. Among the most active species investigated
was the bis chelated diphosphine gold(I) cation, [Au(dppe)2]+ where dppe is Ph2PCH2CH2PPh2
[4, 5]; this complex proved to be a potent cardiovascular toxin [6]. In this context the anti-tumour
activity/cytotoxicity of a series of phosphinegold(I) thiolates have been investigated [7, 8] and we
have reported the in vitro growth inhibitory activity of a series of phosphinegold(I) thionucleobases
with the general formula [R3PAu(SR)], where R Et, Ph or c-hexyl, and SRH 2-mercaptobenzoic
acid, 2-thiouracil, 6-mercaptopurine (6-MPH), or 6-thioguanine (6-TGH) [9]. These latter two
thionucleobases are anticancer drugs that are used clinically in the treatment of leukaemia [10]. All
of the gold complexes showed excellent growth inhibition activity against the L1210 murine
leukaemia in vitro. The activity was generally 10 to 100-fold better than for cisplatin and carboplatin,
the only other metal-containing anticancer drugs in routine clinical use. The development of
resistance to these platinum agents is a significant clinical problem [11], and hence there is a real
need for drugs that are able to circumvent platinum resistance. It is also important to determine
whether potential new agents have activity against human cancer cell lines, and against tumours
growing in mice. Although there was no clear structure-activity relationship in the previous series
[9], two triphenylphosphinegold(I) complexes, i.e. [Ph3PAu(6-MP)] and [Ph3PAu(6-TG)], have
been chosen for further study, and their activity has been investigated against the cisplatin-
resistant L1210 leukaemia, as well as two human carcinoma cell lines, and a murine tumour growing
in vivo.
Materials and Methods.
Materials
The two compounds [Ph3PAu(6-MP)] and [Ph3PAu(6-TG)] were prepared and purified as
described previously [12, 13].
A preliminary crystallographic analysis of [Ph3PAu(6-TG)] [14] shows that the gold atom is
coordinated by the S [Au-S 2.30(1) A] and P [Au-P 2.28(1) A] atoms and exists in a linear geometry
[S-Au-P 175.8(6)]; a close intramolecular Au...N interaction of 3.23(1) A is noted. This structure is
analogous to that of the previously determined [Ph3PAu(6-MP)] complex [13]. As well as the gold
complexes, the free thionucleobaseS were tested, as was Ph3PAuCI. Cis-.
diamminedichloroplatinum(ll) (Institute of Drug Technology, Melbourne, Australia) was used as a
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R H: [Ph3PAu(6-MP)]
R NH2: [Ph3PAu(6-TG)]
In vitro mouse leukaemia growth inhibition assays
Sensitive (L1210) or cisplatin-resistant (L1210/DDP) mouse leukaemia cells were grown as
suspension cultures in Eagle’s minimum essential medium (MEM) plus 1% glutamine and 10%
foetal calf serum (FCS, Flow Laboratories). All compounds were dissolved in dimethylsulfoxide
(dmso) at 9 concentrations over a 3-log range, with a final maximum dmso concentration in the
growth medium of 0.5%. Using 24-well Costar dishes, exponentially growing cells (5 x 104 cells/ml)
were incubated with drugs at each concentration in duplicate at 37 C in a humidified incubator
gassed with 5% CO2/95% air for 48 hr. Cell numbers were then counted with a Coulter counter
(model ZM). The average number of cells in each duplicate drug-treated culture was then
expressed as a percentage of the quadruplicate vehicle-treated control. The IC50 value in pM,
defined as the concentration of compound required to inhibit 50% of the cell growth after 48 hr of
drug exposure, was calculated graphically.
In vitro human carcinoma growth inhibition assays
The SKOV-3 human ovarian carcinoma cell line was maintained in o-MEM plus 15% FCS. The
FaDu human squamous cell carcinoma of the hypopharynx w.as maintained in RPMI plus 10% FCS.
" For the growth inhibition studies, 5 x 103 SKOV-3 or x 10 FaDu exponent’ally growing cells in
100 ml medium were allowed to adhere in 96-well culture plates for 12 to 16 hr at 37 C in a
humidified incubator (gassed as above). Drugs were dissolved in dmso and diluted in medium to
10 concentrations over a 4-log range, and 100 ml of each drug solution was added to 5 wells. Cells
were incubated for a further 72 hr, after which viable cells were measured using the sulforhodamine
B (SRB) assay [15] that measures cellular protein content. Briefly, cells were fixed with
trichloroacetic acid and stained with SRB. Unbound dye was removed by washing with acetic acid,
protein-bound dye was solubilised with Tris base, and the optical density was read at 550 nm using
an automatic plate reader. The percentage growth inhibition was calculated as above.
In vivo mouse anti-tumour activity
Female Balb/c mice (10-15 weeks) were maintained in controlled atmospheric conditions and fed
standard mouse chow and water ad lib. The protocol was approved by the Institutional Animal
Experimentation and Ethics Committee. The murine PC6 plasmacytoma (obtained from L. Kelland,
Institute of Cancer Research, Sutton, UK) was inoculated as mm cubes subcutaneously on the
flanks of the mice, and approximately 20 days later, mice with tumours were randomised into groups
of 5 to 10 animals, which received either nothing (no-drug control), or an intraperitoneal injection of
dmso at 2.5 ml/kg (vehicle control), cisplatin in saline at 8 mg/kg (positive control), or the test drugs
at the maximum tolerated dose at 2.5 ml/kg in dmso. Eight to ten days later, mice were sacrificed
and the tumours were dissected and weighed. The compounds tested against this tumour were
[Ph3PAuCI], [6-MPH], [Ph3PAu(6-MP)] and cisplatin.
Results.
In vitro growth inhibition
The results for the in vitro growth inhibition studies are summarised in Table 1. The gold complexes
[Ph3PAuCI] and [Ph3PAu(6-MP)] were both active against the cisplatin-resistant L1210, whereas
[6-MPH] lost its activity. The gold complexes were both active against the human cell lines,
whereas the free thionucleobases were not. The presence of the thionucleobase within the gold
complex did not add to the activity against the SKOV-3 cells.
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Table 1. In vitro growth inhibition activity.
Compound L1210 L1210/DDP FaDu SKOV-3
[Ph3PAuCI] 0.30 0.14 n.d.
[6-MPH] 0.310" 3.3 >5
[Ph3PAu(6-MP)] 0.083* 0.05 0.25
[6-TGH] 0.096* n.d. >2
[Ph3PAu(6-TG)] 0.052* n.d. 0.39
Cisplatin 0.6 6.7 6.1
0.13
19.5
0.36
9.1
0.63
3.1
Values are the IC50 in #M of 2 to 5 experiments.
n.d. not done.
these results have been published previously [9]
In vivo anti-tumour activity
[6-MPH] at 50 mg/kg and [Ph3PAuCI] at 25 mg/kg were not effective in reducing the size of the
PC6 tumours. However, treatment with a single dose of [Ph3PAu(6-MP)] at 25 mg/kg led to a 60%
reduction in tumour size. Although the decrease seen with [Ph3PAu(6-MP)] was statistically
significant (P=0.006, one way analysis of variance), cisplatin was able to cure all of the mice.
Discussion.
The [Ph3PAu(6-MP)] complex showed impressive activity against the cisplatin-resistant cells.
There are several reported mechanisms of platinum resistance in this L1210/DDP cell line,
including reduced drug uptake, increased intracellular glutathione levels, and increased DNA repair
following platination [16 18]. It is not clear which mechanism is most important in the present case,
but it is apparent that the addition of the thionucleobase to the gold complex is not necessary to
overcome the cisplatin resistance, as [Ph3PAuCI] was also found to have some activity, although
not as pronounced. The complexes [Ph3PAu(6-MP)] and [Ph3PAu(6-TG)] showed equivalent
activity against both of the human cell lines, whereas the free thionucleobases were inactive.
Again, addition of the thionucleobase to the complexes did not enhance this activity.
Despite the encouraging in vitro growth inhibition activity, the in vivo results were disappointing.
Activity at least as good as cisplatin against animal tumours would ensure a positive response
towards further development. Complexes of the general structure R3PAuSR, such as Auranofin
[2346-tetra--acety-1-thi--D-gucpyransat-S-triethyphsphinegd()] have been shown
to have cytotoxic activity in vitro, but only limited in vivo anti-tumour activity [7, 19]. Other gold(I)
coordination complexes have also been screened, however, in general their in vivo activity is low
[20]. This lack of in vivo activity may be attributed to the ability of linear gold(I) complexes to
undergo rapid ligand-exchange reactions with endogenous thiols in the plasma [21], thus
decreasing their availability for cytotoxic activity. For example, decreased in vitro activity has been
demonstrated for both Auranofin [7] and triphenylphosphinegold(I) 8-thiotheophyllinate [8] when
increasing concentrations of albumin were present in the growth medium. Thus, further in vitro
studies with these triphenylphosphinegold(I) thionucleobases will be necessary to assess their
reactivity with biological solutions. In addition, it is important to determine the mechanism of action
of these compounds in order to guide further development and testing.
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